Nusinersen versus sham control in later-onset spinal muscular atrophy
<p><strong>Background:</strong><br /> Nusinersen is an antisense oligonucleotide drug that modulates pre–messenger RNA splicing of the survival motor neuron 2 (SMN2) gene. It has been developed for the treatment of spinal muscular atrophy (SMA).</p><br /> <p&g...
Main Authors: | Mercuri, E, Darras, BT, Chiriboga, CA, Day, JW, Campbell, C, Connolly, AM, Iannaccone, ST, Kirschner, J, Kuntz, NL, Saito, K, Shieh, PB, Tulinius, M, Mazzone, ES, Montes, J, Bishop, KM, Yang, Q, Foster, R, Gheuens, S, Bennett, CF, Farwell, W, Schneider, E, De Vivo, DC, Finkel, RS |
---|---|
Format: | Journal article |
Language: | English |
Published: |
Massachusetts Medical Society
2018
|
Similar Items
-
Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy
by: Finkel, RS, et al.
Published: (2017) -
Scientific rationale for a higher dose of nusinersen
by: Richard S. Finkel, et al.
Published: (2022-06-01) -
Nusinersen Treatment of Children with Later-Onset Spinal Muscular Atrophy and Scoliosis Is Associated with Improvements or Stabilization of Motor Function
by: Sally Dunaway Young, et al.
Published: (2023-07-01) -
Nusinersen in pediatric and adult patients with type III spinal muscular atrophy
by: Maria Carmela Pera, et al.
Published: (2021-08-01) -
Motor function in type 2 and 3 SMA patients treated with Nusinersen: a critical review and meta-analysis
by: Giorgia Coratti, et al.
Published: (2021-10-01)